Severe hypercalcemia in a patient with chronic lymphocytic leukemia and non-small cell lung carcinoma

Abstract Rationale: Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. In this paper, we report on a patient with advanced chronic lymphocytic leukemia and non-small cell lung carcinoma who developed severe hypercalcemia and discuss the diagnosis and treatment of this metabolic complication. Patient concerns: A 56-year old male with a 2-year history of Rai stage IV chronic lymphocytic leukemia presented with life-threatening hypercalcemia. Positron emission tomography/computed tomography revealed a suspicious lung lesion. A transbronchial biopsy was performed from the upper left lobe. Due to the small size of the specimen, immunohistochemical markers were performed and revealed positive staining for cytokeratin 7 and negative for TTF-1, napsin A and p 40, which were consistent with non-small cell lung carcinoma. Diagnosis: Humoral hypercalcemia of malignancy was diagnosed. Intervention: The patient was treated with saline infusion, calcitonin, intravenous pamidronate, followed with denosumab. Outcomes: The hypercalcemia was successfully treated and the patient's calcium levels returned to normal. Further evaluation revealed a non-small cell lung carcinoma as a second primary malignancy. The patient was treated with venetoclax for his refractory CLL and received chemotherapy and immunotherapy for lung adenocarcinoma. Several days after starting venetoclax, he developed Legionella pneumonia and short time after the second course of chemotherapy, a severe sepsis occurred and he passed away. Lessons: Coexistence of 2 unrelated malignancies, whichever could be a reason for hypercalcemia of malignancy is a rare event. Severe hypercalcemia, which is possible but rare feature of CLL should be a reason for further prompt evaluation.

[1]  J. Bergler-Klein Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends. , 2019, Journal of the American College of Cardiology.

[2]  Yanwei Xing,et al.  Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. , 2019, Heart rhythm.

[3]  L. Larocca,et al.  Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia , 2018, Hematological oncology.

[4]  N. Komatsu,et al.  Usage and Distribution for Commercial Purposes Requires Written Permission. Richter's Syndrome with Hypercalcemia Induced by Tumor-associated Production of Parathyroid Hormone-related Peptide , 2022 .

[5]  E. Koutroumpakis,et al.  Symptomatic Hypercalcemia in a Patient with B-cell Chronic Lymphocytic Leukemia - A Case Report and Review of the Literature. , 2016, In vivo.

[6]  A. Liede,et al.  Prevalence of hypercalcemia among cancer patients in the United States , 2016, Cancer medicine.

[7]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[8]  A. Liede,et al.  Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the Clinical Practice Research Datalink database. , 2015, Cancer epidemiology.

[9]  A. Mirrakhimov Hypercalcemia of Malignancy: An Update on Pathogenesis and Management , 2015, North American journal of medical sciences.

[10]  J. Jones,et al.  PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab. , 2015, Clinical lymphoma, myeloma & leukemia.

[11]  A. Neugut,et al.  Quality and Outcomes of Treatment of Hypercalcemia of Malignancy , 2015, Cancer investigation.

[12]  S. Minisola,et al.  The diagnosis and management of hypercalcaemia , 2015, BMJ : British Medical Journal.

[13]  D. McLeod,et al.  PTHrP-mediated hypercalcemia: causes and survival in 138 patients. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  A. Akçay,et al.  The coexistence of renal cell carcinoma and diffuse large B-cell lymphoma with hypercalcemic crisis as the initial presentation. , 2014, Endocrine Regulations.

[15]  R. Jain,et al.  Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment , 2013, Journal of the National Cancer Institute.

[16]  W. Schmiegel,et al.  A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced by Elevated Parathyroid Hormone-Related Peptides , 2010, Acta Haematologica.

[17]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[18]  P. Kostenuik,et al.  The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. , 2005, Endocrinology.

[19]  A. F. Stewart Hypercalcemia Associated with Cancer , 2005 .

[20]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Antoine Martin,et al.  Hypercalcemia may indicate Richter's syndrome , 1997, Cancer.

[22]  D. Meseure,et al.  Hypercalcaemia in B cell chronic lymphocytic leukaemia , 1994, British journal of haematology.

[23]  B. Schöttker,et al.  Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma. , 2006, Haematologica.

[24]  P. Pauwels,et al.  Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. , 1999, The Netherlands journal of medicine.